Indication: For the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as
may occur in adult patients with overactive bladder (OAB) syndrome.
Contraindication: Mirabegron (Betmiga®,) is contraindicated in patients with:
- Hypersensitivity to the active substance or to any of the excipients listed in List of excipients.
- Severe uncontrolled hypertension defined as systolic blood pressure &ge,180 mm Hg and/or diastolic blood pressure &ge,110 mm Hg.

Place of Origin

The Netherlands

Directions

The recommended dose is 50 mg once daily with or without food.

Ingredients

List of excipients
Core tablet

Warnings

May increase BP. Patients w/ congenital or acquired QT prolongation